Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asunercept in Hospitalized Moderate to Severe COVID-19
NCT05639192Phase 3Terminated
- Sponsor
- Apogenix
- Start
- Nov 2022
- Primary completion
- Aug 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Standard of Care + Asunercept 100 mg with Standard of Care + Placebo (2 arms). Primary endpoint: Time to sustained recovery. Started Nov 2022; status: terminated.
02
Drugs
asunercept
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05639192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05639192.